Jermie E Cozart

Array ( [id] => 16253441 [patent_doc_number] => 20200262815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => THERAPEUTIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/694332 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16694332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16504691 [patent_doc_number] => 20200383947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER [patent_app_type] => utility [patent_app_number] => 16/684170 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822644 [patent_doc_number] => 20210137937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => METHOD OF TREATMENT OF CIRRHOSIS [patent_app_type] => utility [patent_app_number] => 16/677756 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16677756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895179 [patent_doc_number] => 20200147108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => METHODS OF USING OBETICHOLIC ACID [patent_app_type] => utility [patent_app_number] => 16/675604 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15862855 [patent_doc_number] => 20200138831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => OXYGENATED CHOLESTEROL SULFATES FOR THERAPY OF DISORDERS CAUSED BY AT LEAST ONE OF ATTENUATED LEPTIN ACTIVITY AND A LIPID STORAGE DISORDER [patent_app_type] => utility [patent_app_number] => 16/593460 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363469 [patent_doc_number] => 20200017499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => NOVEL COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/585251 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16585251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15708621 [patent_doc_number] => 20200101076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OR TREATMENT OF CYTOKINE RELEASE SYNDROME [patent_app_type] => utility [patent_app_number] => 16/582316 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7622 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16582316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17680011 [patent_doc_number] => 11364242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-21 [patent_title] => Treatment agents for inhibiting HIV and cancer in HIV infected patients [patent_app_type] => utility [patent_app_number] => 16/580988 [patent_app_country] => US [patent_app_date] => 2019-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 27 [patent_no_of_words] => 14661 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16580988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267401 [patent_doc_number] => 20200268888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE [patent_app_type] => utility [patent_app_number] => 16/578148 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16578148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649621 [patent_doc_number] => 20200087340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => LIF/LIFR ANTAGONIST IN ONCOLOGY AND NONMALIGNANT DISEASES [patent_app_type] => utility [patent_app_number] => 16/569993 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16569993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527071 [patent_doc_number] => 20200055841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => METHODS OF TREATING INFLAMMATION OR NEUROPATHIC PAIN [patent_app_type] => utility [patent_app_number] => 16/563733 [patent_app_country] => US [patent_app_date] => 2019-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16563733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420499 [patent_doc_number] => 20200345697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => USE OF PROSTACYCLIN ANTAGONISTS FOR TREATING OCULAR SURFACE NOCICEPTION [patent_app_type] => utility [patent_app_number] => 16/562063 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16562063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17466680 [patent_doc_number] => 11273137 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene [patent_app_type] => utility [patent_app_number] => 16/560026 [patent_app_country] => US [patent_app_date] => 2019-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17442 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16560026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236682 [patent_doc_number] => 20200253916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => Compositions of Azadirachta Indica and Methods of Treating Cancer [patent_app_type] => utility [patent_app_number] => 16/557028 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16557028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293327 [patent_doc_number] => 20190389799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => TYPE III DEIODINASE INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/553647 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16553647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15263743 [patent_doc_number] => 20190380605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => Method of Administering Sotalol IV/SWITCH [patent_app_type] => utility [patent_app_number] => 16/549620 [patent_app_country] => US [patent_app_date] => 2019-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16549620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16655902 [patent_doc_number] => 20210052538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => TINTED COLD SORE FORMULATION [patent_app_type] => utility [patent_app_number] => 16/550000 [patent_app_country] => US [patent_app_date] => 2019-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16550000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206035 [patent_doc_number] => 20190365704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 16/538175 [patent_app_country] => US [patent_app_date] => 2019-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16538175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15239535 [patent_doc_number] => 20190374553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => HIGH CONCENTRATION FORMULATION [patent_app_type] => utility [patent_app_number] => 16/529214 [patent_app_country] => US [patent_app_date] => 2019-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16529214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16466698 [patent_doc_number] => 20200368235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => IBRUTINIB COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/529467 [patent_app_country] => US [patent_app_date] => 2019-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16529467 [rel_patent_id] =>[rel_patent_doc_number] =>)